Men with stable coronary artery disease (CAD) enjoying the benefits of phosphodiesterase-5 (PDE-5) inhibitors, such as Viagra or sildenafil, to treat erectile dysfunction stand to gain an even more worthwhile benefit-lesser risk for a worsened heart ailment.
In a Swedish registry study published in the Journal of the American College Of Cardiology, men taking these inhibitors for their erectile dysfunction (ED) would less likely have a myocardial infarction (MI), coronary revascularization, or heart failure than those ED patients who are receiving alprostadil.
PDE-5 Erectile Dysfunction Treatment Lowers Heart Disease Risk
With impotence becoming a massive problem among older men who had suffered from CAD, these findings prove to be a huge blessing for the age demographic as it further lowers their risk of further heart illness.
